Prøve GULL - Gratis

Malaria, Dengue TB Play Second Fiddle To Covid - 19

Bio Spectrum

|

June 2021

Although India has worked relentlessly towards developing innovative testing solutions for COVID-19 throughout last year, the timely detection of a number of other infectious diseases has been sidelined. In India, the range and burden of infectious diseases such as tuberculosis, malaria, filariasis, leprosy, HIV infection, typhoid, hepatitis etc., are enormous. In fact, inadequate containment of the vector has resulted in recurrent outbreaks of dengue fever and re-emergence of chikungunya virus disease and typhus fever. If India can develop more than 20 different diagnostic tests or devices in a single year to fight COVID-19, many more such innovations can be brought to effectively detect other infections looming in our country.

- Dr Manbeena Chawla

Malaria, Dengue TB Play Second Fiddle To Covid - 19

Like the previous year, 2021 is expected to be dominated by the coronavirus pandemic. Apart from the difficulties it has imposed on the healthcare system, it has made India realise the importance of biomedical resources. It has pushed India to optimise the latent capabilities which the country possesses, across the public and private sector to promote indigenous development and manufacturing.

2020 saw many innovative solutions entering the market within the diagnostic space particularly for COVID-19 testing. A majority of them came from the academic sector, after receiving timely regulatory approvals and commercialisation.

Although India worked relentlessly towards developing innovative testing solutions for COVID-19 throughout last year, the timely detection of a number of other infectious diseases got sidelined. A recent example is the rise of a rare fungal infection mucormycosis.

In India, the range and burden of infectious diseases are enormous such as tuberculosis, malaria, filariasis, leprosy, HIV infection, typhoid, hepatitis etc. In fact, inadequate containment of the vector has resulted in recurrent outbreaks of dengue fever and reemergence of chikungunya virus disease and typhus fever.

For instance, India is home to approximately 2.8 million tuberculosis patients, making it the largest number in a single country. On the other hand, more than a decade after India eliminated leprosy, the disease continues to linger on. Adding on, India’s malaria surveillance system ranks among the worst in the world according to the World Health Organization (WHO). According to a study published in The Lancet in 2020, diarrheal diseases, tuberculosis and lower respiratory infections were among the leading causes of deaths in India in 2019.

FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum

Bio Spectrum

Navigating the Complexities of Pharma Packaging Sustainability

Pharma companies in India are increasingly adopting sustainable methods in packaging to ensure that medicines remain safe and the environment is protected. Various initiatives by the government, focusing on reducing carbon footprints, are revolutionising the pharma packaging industry.

time to read

8 mins

September 2025

Bio Spectrum

Bio Spectrum

Are BioStartUps in a Funding/Innovation Rut?

At the BioStartUps Founders & Investors Forum 2025, held on August 1, 2025 at the CIDCO Exhibition Centre in Vashi, Navi Mumbai, biotech industry stalwarts deliberated on the country's innovation and startup ecosystem.

time to read

10 mins

September 2025

Bio Spectrum

Bio Spectrum

How Do Recent Deaths Impact Gene Therapy Development?

Cell and gene therapy (CGT) is among the most closely watched areas in pharma and biotech.

time to read

4 mins

September 2025

Bio Spectrum

Bio Spectrum

HealthQuad appoints Namit Chugh as Director

Quadria Group, Asia's leading healthcare-focused private equity platform, has announced the appointment of Namit Chugh as Director at HealthQuad, India's leading healthcare-focused growth venture capital platform.

time to read

1 min

September 2025

Bio Spectrum

Bio Spectrum

Why Is Endoscopy Crucial for Gl Cancer Diagnosis?

The increased demand for gastrointestinal (GI) diagnostics in India, driven by rising disease rates and awareness of early intervention, is not evenly distributed. While major urban hospitals have expanded their endoscopic capabilities, many semi-urban and rural areas face limited access. Addressing this disparity is crucial for extending the benefits of early disease detection across the country.

time to read

4 mins

September 2025

Bio Spectrum

New England Biolabs launches NEBNext low-bias small RNA library prep kit

US-based New England Biolabs (NEB) has announced the launch of the NEBNext Low-bias Small RNA Library Prep Kit, designed to minimise biased representation of small RNA species in sequencing data.

time to read

1 min

September 2025

Bio Spectrum

Bio Spectrum

Qiagen expands NGS portfolio with launch of QIAseq XHYB long read panels

Qiagen has announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions.

time to read

1 min

September 2025

Bio Spectrum

Bio Spectrum

"Awareness and consistent training are needed with the growing demand for effective skin treatments in India"

India’s dermatology and aesthetic market is reportedly among the fastest-growing globally, projected to grow at a CAGR of 10.11 per cent from 2025 to 2032.

time to read

4 mins

September 2025

Bio Spectrum

Dr. Moopen's Legacy Scholarship & Fellowships to aid 25 students from across India

In a path breaking initiative to make medical education accessible to meritorious students and students from economically challenged backgrounds, Padma Shri Dr Azad Moopen, Founder & Chairman of Aster DM Healthcare and a globally recognised philanthropist, has announced an annual scholarship programme Dr. Moopen's Legacy Scholarship & Fellowships Programme aimed at supporting meritorious students seeking admissions in Dr. Moopen's Medical College, Dr Moopen's Nursing College and Dr Moopen's College of Pharmacy in Wayanad, Kerala.

time to read

1 min

September 2025

Bio Spectrum

Bio Spectrum

Iberia Pharma set to open manufacturing unit in India with investment of Rs 70 Cr

Gurugram-based Iberia Pharmaceuticals has announced its new hi-tech manufacturing and research facility spread across 60,000 sq. ft. in Jhajjar, Haryana.

time to read

1 min

September 2025

Translate

Share

-
+

Change font size